UK competition regulator looking into $39 bln AstraZeneca-Alexion deal
Britain’s competition regulator is reviewing AstraZeneca’s (AZN.L) $39 billion buyout of U.S.-based Alexion (ALXN.O) on concerns it could reduce competition in the UK market or elsewhere.
